肝病

订阅

MedSci主页 / 所有栏目 / 肝病

2012 APASL会议日程

2012-02-17 MedSci MedSci原创

APASL会议
关注

2012 APASL会议日程

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2058273, encodeId=7c7120582e336, content=<a href='/topic/show?id=38aa258182a' target=_blank style='color:#2F92EE;'>#会议日程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25818, encryptionId=38aa258182a, topicName=会议日程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 16 20:56:00 CST 2012, time=2012-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338106, encodeId=102b133810649, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519122, encodeId=a0e8151912225, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598421, encodeId=6dfa15984215b, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2625, encryptionId=a8952625e5, topicName=APASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b18118584502, createdName=tongyongming, createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-12-16 cenghis

    #会议日程#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2058273, encodeId=7c7120582e336, content=<a href='/topic/show?id=38aa258182a' target=_blank style='color:#2F92EE;'>#会议日程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25818, encryptionId=38aa258182a, topicName=会议日程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 16 20:56:00 CST 2012, time=2012-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338106, encodeId=102b133810649, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519122, encodeId=a0e8151912225, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598421, encodeId=6dfa15984215b, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2625, encryptionId=a8952625e5, topicName=APASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b18118584502, createdName=tongyongming, createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-02-19 12498b3em08(暂无昵称)

    #APA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2058273, encodeId=7c7120582e336, content=<a href='/topic/show?id=38aa258182a' target=_blank style='color:#2F92EE;'>#会议日程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25818, encryptionId=38aa258182a, topicName=会议日程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 16 20:56:00 CST 2012, time=2012-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338106, encodeId=102b133810649, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519122, encodeId=a0e8151912225, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598421, encodeId=6dfa15984215b, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2625, encryptionId=a8952625e5, topicName=APASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b18118584502, createdName=tongyongming, createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-02-19 lq1771

    #ASL#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2058273, encodeId=7c7120582e336, content=<a href='/topic/show?id=38aa258182a' target=_blank style='color:#2F92EE;'>#会议日程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25818, encryptionId=38aa258182a, topicName=会议日程)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Sun Dec 16 20:56:00 CST 2012, time=2012-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338106, encodeId=102b133810649, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519122, encodeId=a0e8151912225, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598421, encodeId=6dfa15984215b, content=<a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2625, encryptionId=a8952625e5, topicName=APASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b18118584502, createdName=tongyongming, createdTime=Sun Feb 19 09:56:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-02-19 tongyongming

    #APASL#

    0

相关资讯

APASL将发乙丙肝新指南

专家合影 　　2012年第22届亚太肝脏研究学会年会共有来自全球56个国家的3000位以上医师和研究人员参加，逾150位学者专家受邀演讲，投稿论文篇数高达1018篇，会中不仅探讨多项肝病重大议题外，还将同时发布乙型、丙型肝炎最新治疗指南。